The Government of India has issued detailed guidance on the use, risks, and regulatory framework for GLP-1 (Glucagon-Like Peptide-1) drugs, prescription medications used to manage type 2 diabetes and obesity. The move comes amid rising concerns over unsupervised sales through pharmacies, wellness clinics, and online platforms.
Key Highlights
GLP-1 drugs are prescription only and can be prescribed only by endocrinologists, cardiologists, and internal medicine specialists. Over-the-counter sales are prohibited.The Drug Controller General of India (DCGI), in collaboration with State Drug Controllers, has intensified inspections and warned that non-compliance may lead to license cancellation, fines, and legal action.Patients are advised to use these medications strictly under medical supervision due to potential side effects, ranging from nausea and digestive issues to rare but serious complications such as pancreatitis and kidney injury.Also Read: Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge generics
Understanding GLP-1 Drugs
GLP-1 receptor agonists address hormonal imbalances in type 2 diabetes, stimulating insulin release and suppressing glucagon, while also slowing gastric emptying to reduce appetite. This dual action not only helps regulate blood sugar but also promotes weight loss.
Live Events
Common GLP-1 drugs available in India include Semaglutide (injection and oral), Liraglutide, Tirzepatide, Dulaglutide, and Exenatide.
How They WorkFood intake triggers the release of GLP-1 hormone from the intestines.GLP-1 signals the pancreas to release insulin and suppress glucagon.The drugs mimic this process, controlling blood sugar and prolonging satiety.Side Effects and RisksMild: Loss of appetite, nausea, vomiting, diarrhea, constipation.Moderate: Dizziness, headaches, infections, mild increase in heart rate.Severe/Rare: Pancreatitis, thyroid cancer, kidney injury, gallbladder disease, delayed gastric emptying.Rapid weight loss may also cause “Ozempic face”, with visible changes in facial fat and skin. Pregnant women are advised against using these drugs without medical guidance, as per the government release.
Also Read: Want to lose weight? New study reveals how your body can burn fat faster instead of storing it
Government Regulations
Only qualified specialists can prescribe GLP-1 drugs.Advisory issued March 10, 2026: Ban on misleading advertisements, crackdown on unauthorized sales, nationwide inspections of pharmacies, clinics, and warehouses.Enforcement includes fines, license cancellation, and legal action for violations.While GLP-1 drugs represent a significant advancement in managing type 2 diabetes and obesity, their use must be closely supervised. The DCGI’s latest advisory reinforces the need for strict compliance by healthcare providers and pharmacists to prevent misuse and safeguard patient health.